283 related articles for article (PubMed ID: 34503725)
1. Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma.
Bruce WJ; Koljonen JL; Romanelli MR; Khan AU; Neumeister MW
Clin Plast Surg; 2021 Oct; 48(4):651-658. PubMed ID: 34503725
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
3. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Melanoma - A Review of Systemic Therapies.
Lee KA; Nathan P
Acta Derm Venereol; 2020 Jun; 100(11):adv00141. PubMed ID: 32346745
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma.
Ponto J; Bell RB
Oral Maxillofac Surg Clin North Am; 2022 May; 34(2):315-324. PubMed ID: 35491081
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
McKean MA; Amaria RN
Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
[TBL] [Abstract][Full Text] [Related]
7. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
12. Educational Review: Neoadjuvant Approaches to Melanoma.
Sharon CE; Karakousis GC
Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Therapy for Melanoma.
Wada-Ohno M; Ito T; Furue M
Curr Treat Options Oncol; 2019 Jun; 20(8):63. PubMed ID: 31236710
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy for Melanoma.
Lowe MC; Kudchadkar RR
Surg Oncol Clin N Am; 2020 Jul; 29(3):445-453. PubMed ID: 32482319
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
19. Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
Indini A; Roila F; Grossi F; Massi D; Mandalà M
Am J Clin Dermatol; 2021 Jul; 22(4):511-522. PubMed ID: 34036489
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
Mueller KL; Theoret MR; Lemery SJ; Amiri-Kordestani L; Ariyan CE; Atkins MB; Berry DA; Blank CU; DeMichele AM; Forde PM; Ibrahim N; Keegan P; Mitchell TC; Moss RA; Robert C; Sridhara R; Taube JM; Tetzlaff MT; Wargo JA; Flaherty KT; Kaplan MJ; Topalian SL; Ward AF; Hurlbert MS
Clin Cancer Res; 2021 Jan; 27(2):394-401. PubMed ID: 33188142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
